A+ A A-

Download article

Sergiyevich A.V.
Clinical and laboratory peculiarities of patients with psoriasis
Education Establishment "Vitebsk State Order of Peoples’ Friendship Medical University", Republic of Belarus

Psoriasis is widespread, hereditary, T-cellular, chronic dermatosis with the benign hyperproliferation of epitheliocytes, the disturbance of their differentiation and keratinization as well as with organs and systems pathology. 56 persons with psoriasis without joints lesion were included in this research. The control group consisted of 26 healthy people. In persons with psoriasis without joints lesion the serumal level of arginase I was statistically significantly  higher, than that in the control group; statistically significant moderate positive correlation between TNF-e, IL-1, and IL-6 was found; proatherogenic changes of lipide profile indices (increase of serumal levels of TC, LDL-C, TG, VLDL-C and decrease of serumal level of HDL-C) were determined. For the group with psoriasis moderate positive correlation of arginase I with PASI index and age; TC, TG, VLDL-C with the patients’ age was revealed.
Key words: psoriasis, arginase I, interleukins, lipids.


1. Martyn-Simmons CL, Ranawaka RR, Chowienczyk P, Crook MA, Marber MS, Smith CH, Barker JN. A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. British Journal of Dermatology. 2011 Jan;164(1):26–32.
2. Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis results from a randomized, placebo-controlled phase II trial. American Journal of Clinical Dermatology. 2003;4(2):131–9.
3. Kozha i serdtse. Priamaia sviaz' [The skin and heart. Direct link] [Elektronnyi resurs]. [sait]. 2006. Rezhim dostupa: Data dostupa: 03.04.2014.
4. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol. 2000 Nov-Dec;80(6):430-4.
5. Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC. Lipid disturbances in psoriasis: an update. Mediators of Inflammation [Electronic resource]. 2010. Mode of access: Date of access: 01.04.2014.
6. Psoriaz [Psoriasis] [Elektronnyi resurs]. Grodnenskii oblastnoi kozhno-venerologicheskii dispanser: [sait]. Rezhim dostupa: Data dostupa: 29.03.2014.
7. Gutierrez M, De Angelis R, Bernardini ML, Filippucci E, Goteri G, Brandozzi G, Lemme G, Campanati A, Grassi W, Offidani A. Clinical, power Doppler sonography and histological assessment of the psoriatic plaque: short-term monitoring in patients treated with etanercept. Br J Dermatol. 2011 Jan;164(1):33-7.
8. Borska L, Fiala Z, Krejsek J, Andrys C, Vokurkova D, Hamakova K, Kremlacek J, Ettler K. Immunologic changes in TNF-alpha, sE-selectin, sP-selectin, sICAM-1, and IL-8 in pediatric patients treated for psoriasis with the Goeckerman regimen. Pediatr Dermatol. 2007 Nov-Dec;24(6):607-12.
9. Morken T, Bohov P, Skorve J, Ulvik R, Aukrust P, Berge RK, Livden JK. Anti-inflammatory and hypolipidemic effects of the modified fatty acid tetradecylthioacetic acid in psoriasis – a pilot study. Scand J Clin Lab Invest. 2011 Jul;71(4):269-73.
10. O'Kane M, Markham T, McEvoy AN, Fearon U, Veale DJ, FitzGerald O, Kirby B, Murphy EP. Increased expression of the orphan nuclear receptor NURR1 in psoriasis and modulation following TNF-alpha inhibition. J Invest Dermatol. 2008 Feb;128(2):300-10.
11. Cohen AD, Dreiher J, Shapiro Y, Vidavsky L, Vardy DA, Davidovici B, Meyerovitch J. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2008 May;22(5):585-9.
12. Balato N, Di Costanzo L, Ayala F, Balato A, Sanduzzi A, Bocchino M. Psoriatic disease and tuberculosis nowadays. Clinical and Developmental Immunology [Electronic resource]. 2012. Mode of access: Date of access: 01.04.2014.
13. Psoriaz sviazan s povyshennym riskom infarkta miokarda [Psoriasis is associated with an increased risk of myocardial infarction] [Elektronnyi resurs]. [sait]. 2006. Rezhim dostupa: Data dostup: 03.04.2014.
14. Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled phase III study. Health and Quality of Life Outcomes [Electronic resource]. 2008;75(6). Mode of access: Date of access: 27.03.2014.
15. Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol. 2011 Feb;12(1):51-62.
16. MacDonald A, Burden AD. Psoriasis: advances in pathophysiology and management. Postgrad Med J. 2007 Nov;83(985):690-7.
17. Papoutsaki M, Osório F, Morais P, Torres T, Magina S, Chimenti S, Costanzo A. Infliximab in psoriasis and psoriatic arthritis. BioDrugs. 2013 Jan;27 Suppl 1:13-23.
18. Gottlieb AB, Antoni CE. Treating psoriatic arthritis: how effective are TNF antagonists? Arthritis Res Ther. 2004;6 Suppl 2:S31-5.
19. Kivelevitch D, Mansouri B, Menter A. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics. 2014 Apr;8:169-82.
20. Fiorino G, Allez M, Malesci A, Danese S. Review article: anti TNF-a induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009 May;29(9):921-7.
21. Spadaro A, Montepaone M, Lubrano E. A novel biological target for the treatment of psoriatic arthritis. Immunotherapy. 2014 May;6(5):515-8.
22. Muhr P, Zeitvogel J, Heitland I, Werfel T, Wittmann M. Expression of interleukin (IL)-1 family members upon stimulation with IL-17 differs in keratinocytes derived from patients with psoriasis and healthy donors. Br J Dermatol. 2011 Jul;165(1):189-93.
23. Alsufyani MA, Golant AK, Lebwohl M. Psoriasis and the metabolic syndrome. Dermatol Ther. 2010 Mar-Apr;23(2):137-43.
24. Ramonda R, Puato M, Punzi L, Rattazzi M, Zanon Marta, Balbi G, Ortolan A, Frallonardo P, Faggin E, Plebani M, Zaninotto M, Lorenzin M,  P, Doria A. Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: A two-year prospective observational study. Joint, Bone, Spine [Electronic resource]. 2014. Mode of access: Date of access: 10.04.2014.
25. Campanati A, Orciani M, Consales V, Lazzarini R, Ganzetti G, Di Benedetto G, Di Primio R, Offidani A. Characterization and profiling of immunomodulatory genes in resident mesenchymal stem cells reflect the Th1-Th17/Th2 imbalance of psoriasis. Archives Of Dermatological Research [Electronic resource]. 2014. Mode of access: Date of access: 07.09.2014.
26. Baran W, Szepietowski JC, Mazur G, Baran E. IL-6 and IL-10 promoteir gene polymorphiisms in psoriasis vulgaris. Acta Derm Venereol. 2008;88(2):113-6.
27. Tobin AM, Kirby B. TNFa inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs. 2005;19(1):47-57.
28. Peluso R, Cafaro G, Di Minno A, Iervolino S, Ambrosino P, Lupoli G, Di Minno MN. Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies. Clin Rheumatol. 2013 Jun;32(6):743-53.
29. Derer A, Groetsch B, Harre U, Böhm C, Towne J, Schett G, Frey S, Hueber AJ. Blockade of IL-36 Receptor Signaling Does Not Prevent from TNF-Induced Arthritis. Plos One [Electronic resource]. 2014;9(8). Mode of access: Date of access: 07.09.2014.
30. Frey S, Derer A, Messbacher ME, Baeten DL, Bugatti S, Montecucco C, Schett G, Hueber AJ. The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium. Ann Rheum Dis. 2013 Sep;72(9):1569-74.
31. Ekman AK, Verma D, Fredrikson M, Bivik C, Enerbäck C. Genetic susceptibility of NLRP1 in psoriasis. Br J Dermatol. 2014 Dec;171(6):1517-20.
32. Witte E, Kokolakis G, Witte K, Philipp S, Doecke WD, Babel N, Wittig BM, Warszawska K, Kurek A, Erdmann-Keding M, Kunz S, Asadullah K, Kadin ME, Volk HD, Sterry W, Wolk K, Sabat R. IL-19 is a Component of the Pathogenetic IL-23/IL-17 Cascade in Psoriasis. The Journal Of Investigative Dermatology [Electronic resource]. 2014 Nov;134(11). Mode of access: Date of access: 07.09.2014.
33. Bech R, Otkjaer K, Birkelund S, Vorup-Jensen T, Agger R, Johansen C, Iversen L, Kragballe K, Rømer J. Interleukin 20 protein locates to distinct mononuclear cells in psoriatic skin. Exp Dermatol. 2014 May;23(5):349-52.
34. Chang YT, Chou CT, Yu CW, Lin MW, Shiao YM, Chen CC, Huang CH, Lee DD, Liu HN, Wang WJ, Tsai SF. Cytokine gene polymorphisms in Chinese patients with psoriasis. Br J Dermatol. 2007 May;156(5):899-905.
35. Namazi MR. Possible molecular mechanisms to account for the involvement of tryptase in the pathogenesis of psoriasis. Autoimmunity. 2005 Sep;38(6):449-52.
36. Zhang W, Baban B, Rojas M, Tofigh S, Virmani SK, Patel C, Behzadian MA, Romero MJ, Caldwell RW, Caldwell RB. Arginase activity mediates retinal inflammation in endotoxin-induced uveitis. Am J Pathol. 2009 Aug;175(2):891-902.
37. Santhanam L, Christianson DW, Nyhan D, Berkowitz DE. Arginase and vascular aging. J Appl Physiol (1985). 2008 Nov;105(5):1632-42.
38. Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol. 2007 Sep;34(9):906-11.
39. Tratsiakovicha Y, Yanga J, Gononb AT, Sjöquista P-O, Pernow J. Arginase as a target for treatment of myocardial ischemia-reperfusion injury. European Journal Of Pharmacology. 2013;720(1-3):121–3.
40. Durante W. Role of arginase in vessel wall remodeling. Frontiers In Immunology [Electronic resource]. 2013;4. Mode of access: Date of access: 05.04.2014.
41. Abeyakirthi S, Mowbray M, Bredenkamp N, van Overloop L, Declercq L, Davis PJ, Matsui MS, Weller RB. Arginase is overactive in psoriatic skin. Br J Dermatol. 2010 Jul;163(1):193-6.
42. Lai Y-L, Aoyama S, Nagai R, Miyoshi N, Ohshima1 H. Inhibition of L-arginine metabolizing enzymes by l-arginine-derived advanced glycation end products. J Clin Biochem Nutr. 2010 Mar; 46(2): 177–185.
43. Morris SM. Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol. 2009 Jul;157(6):922-30.
44. Ryoo S, Gupta G, Benjo A, Lim HK, Camara A, Sikka G, Lim HK, Sohi J, Santhanam L, Soucy K, Tuday E, Baraban E, Ilies M, Gerstenblith G, Nyhan D, Shoukas A, Christianson DW, Alp NJ, Champion HC, Huso D, Berkowitz DE. Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res. 2008 Apr;102(8):923-32.
45. El-Mongy S, Fathy H, Abdelaziz A, Omran E, George S, Neseem N, El-Nour N. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. J Eur Acad Dermatol Venereol. 2010 Jun;24(6):661-6.
46. Gupta M, Chari S, Borkar M, Chandankhede M. Dyslipidemia and oxidative stress in patients of psoriasis. Biomedical Research. 2011;22(2):221-4.
47. Wu S, Li WQ, Han J, Sun Q, Qureshi AA. Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. Arthritis Rheumatol. 2014 Feb;66(2):304-10.
48. Antoniou C, Dessinioti C, Katsambas A, Stratigos AJ. Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor-a therapy in a patient with psoriatic arthritis and psoriasis vulgaris. Br J Dermatol. 2007 May;156(5):1090-1.
49. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat. 2008;19(1):5-21.
50. Goldminz AM, Buzney CD, Kim N, Au SC, Levine DE, Wang AC, Volf EM, Yaniv SS, Kerensky TA, Bhandarkar M, Dumont NM, Lizzul PF, Loo DS, Kulig JW, Brown ME, Lopez-Benitez JM, Miller LC, Gottlieb AB. Prevalence of the metabolic syndrome in children with psoriatic disease. Pediatr Dermatol. 2013 Nov-Dec;30(6):700-5.
51. Papagoras C, Markatseli TE, Saougou I, Alamanos Y, Zikou AK, Voulgari PV, Kiortsis DN, Drosos AA. Cardiovascular risk profile in patients with spondyloarthritis. Joint Bone Spine. 2014 Jan;81(1):57-63.
52. Robati RM, Partovi-Kia M, Haghighatkhah HR, Younespour S, Abdollahimajd F. Increased serum leptin and resistin levels and increased carotid intima-media wall thickness in patients with psoriasis: Is psoriasis associated with atherosclerosis? Journal Of The American Academy Of Dermatology [Electronic resource]. 2014. Mode of access: Date of access: 08.09.2014.
53.  Kubanova AA, red; Rossiiskoe obshchestvo dermatovenerologov. Dermatovenerologiia 2010: klinicheskie rekomendatsii [Dermatology 2010: the clinical guidelines]. 4-e izd., pererab. i dop. Moscow, RF: DEKS-Press; 2010. 428 р.
54. Litvinov AV, red. Normy v meditsinskoi praktike [Standards in medical practice]: spravochnoe posobie. Moscow, RF: MEDpress; 2012. 144 р.
55. Lipoproteiny [Lipoproteins] [Elektronnyi resurs]. Laboratorii Kieva i Ukrainy: [sait]. Rezhim dostupa: Data dostupa: 29.03.2014.
56. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-a, IFN-y, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005 Oct;2005(5):273-9.
57. Mastroianni A, Minutilli E, Mussi A, Bordignon V, Trento E, D'Agosto G, Cordiali-Fei P, Berardesca E. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol. 2005 Sep;153(3):531-6.
58. Viguier M, Guigue P, Pagès C, Smahi A, Bachelez H. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Intern Med. 2010 Jul;153(1):66-7.


Поиск по сайту